Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma
Cancer · 2023
DOI: 10.1002/cncr.34754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Ghassan K Abou-Alfa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis C. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Flatiron Health.
Abstract (Originalsprache)
Background
Clinical trials suggest α‐fetoprotein (AFP) reduction may be prognostic among patients with advanced hepatocellular carcinoma. However, the association of AFP reduction with outcomes in real‐world settings is unclear.
Methods
Patients with advanced hepatocellular carcinoma between January 1, 2011, and June 30, 2021, first‐line tyrosine kinase inhibitor, and baseline and posttreatment AFP values (closest to 8 ± 2 weeks after first‐line initiation) were included. AFP reduction was defined as ≥20% decrease from baseline vs
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medicine, Weill Medical College at Cornell University, New York, New York, USA.
- Flatiron Health, Inc., New York, New York, USA.
- Pine Mountain Consulting, LLC, Redding, Colorado, USA.
- Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Hematology and Oncology, Boston Medical Center, Boston, Massachusetts, USA.
ORCID-Profile: Ghassan K Abou-Alfa, Xiaoliang Wang, Richard Kim, Rebecca A Miksad
Förderung
- Flatiron Health
Zitieren
APA
Abou-Alfa, G. K., Wang, X., Parrinello, C. M., Gossai, A., Kim, R., Magee, K., & Miksad, R. A. (2023). Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma. Cancer. https://doi.org/10.1002/cncr.34754
Vancouver
Abou-Alfa GK, Wang X, Parrinello CM, Gossai A, Kim R, Magee K, et al. Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma. Cancer. 2023. doi:10.1002/cncr.34754
BibTeX
@article{AbouAlfa2023,
author = {Abou-Alfa, Ghassan K and Wang, Xiaoliang and Parrinello, Christina M and Gossai, Anala and Kim, Richard and Magee, Kelly and Miksad, Rebecca A},
title = {Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34754}
}
EUVIMED